Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

NCT07630649 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD

Interventions

GENETIC: Ixo-vec

Sponsor

Adverum Biotechnologies, Inc.